The U.S. equity market closed mixed but resilient on Tuesday, July 28, 2026, with the major indices reflecting a cautious bid ahead of tomorrow’s Federal Reserve interest‑rate decision. The S&P 500, Dow 30, and Russell 2000 finished higher, while the Nasdaq Composite slipped as traders rotated away from select growth and chip names into cyclicals and value.

Index performance snapshot

Based on the end‑of‑day readings, the primary U.S. benchmarks closed as follows

• S&P 500 (US500): 7,428.78, up 15.60 points or +0.21%.
• Dow 30: 52,747.32, up 537.24 points or +1.03%.
• Nasdaq Composite: 24,876.91, down 55.17 points or ‑0.22%.
• Russell 2000: 2,953.79, up 5.75 points or +0.20%.

The pattern—blue chips and small caps up, growth‑heavy Nasdaq down—seems to underscore the market’s “quality cyclical” tilt as investors position around the Fed and upcoming data.

Market backdrop

Macro positioning remains dominated by monetary‑policy expectations, with traders calibrating risk around whether the Fed will affirm a higher‑for‑longer stance or hint at eventual easing. A separate market snapshot cited the U.S. benchmark at roughly similar levels, reinforcing that today’s move was more about rotation than outright risk‑on or risk‑off.

Earnings pulse

Ford Motor Co. (F) was in focus after releasing its second‑quarter 2026 earnings, putting autos and broader industrials under the microscope as investors assessed pricing power, EV investment, and margin resilience. Meanwhile, Coca-Cola Co. (KO) reported second‑quarter 2026 results, noting that EPS rose 16% to $1.03 and comparable EPS (non‑GAAP) climbed 11% to $0.97, highlighting the enduring strength of global beverage demand and the benefit of disciplined cost control.

Macro commentary

Today’s tape fits the “good news with a policy overhang” narrative: solid corporate results can still be rewarded, but the breadth and durability of the rally hinge on tomorrow’s Fed messaging. If the Fed signals confidence in the inflation trajectory without leaning more hawkish, leadership could remain with quality growth and defensive consumer names; if the tone is firmer on inflation risk, rate‑sensitive pockets—small caps, homebuilders, and long‑duration software—may struggle despite decent fundamentals. Currently on Polymarket’s Fed dashboard, crowd‑sourced odds still tilt decisively toward no change at the July 29 FOMC meeting, with 73.4% probability assigned to holding the current target range and 26.6% to a 25‑basis‑point hike. Those probabilities frame tomorrow as a “confirmation or surprise” event: confirmation of no change could sustain current sector rotations, while any deviation would force a rapid repricing in rates and equities.

Trading implications

Into tomorrow’s decision, investors appear to be leaning into cash‑flow generative, large‑cap cyclicals (as reflected in the Dow’s outperformance) while trimming exposure to higher‑beta growth and select chip names captured in the Nasdaq’s decline. For near‑term positioning, the focus will be on:

• Companies with visible earnings trajectories and balance‑sheet strength.
• Sectors that can weather either a steady or slightly higher policy rate environment.
• Opportunistic entries around names that over‑react to Fed language but retain long‑term secular drivers.

Company Note

One company-specific catalyst worth noting was T3 Defense Inc. (Nasdaq: DFNS, $24, +83.21% on Tuesdayand up 265.30% over the last 5-days), whose subsidiary ITS delivered a custom composite materials production line to a leading Israeli building materials manufacturer. The announcement highlights how execution-driven milestones can create attention for smaller industrial and defense-linked names even on a broad market day dominated by index performance. For investors and readers, the key takeaway is that Monday’s close showed underlying resilience in U.S. equities, but the market is still being driven by a combination of macro relief, earnings scrutiny, and selective stock-specific catalysts.

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $11.09, +.36% on Friday.

Hudson Pacific Properties (NYSE: HPP)

Hudson Pacific Properties (NYSE: HPP, $14.11) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $6.10) a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (July 7) the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. “We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.”   said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “Their collective expertise across late-stage drug development, commercial strategy, and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology.”

Eupraxia announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $2.34, +1.30%), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, today (July 22) announced the formation of its Pivot Innovation Council, a cross-functional group of leading clinicians and healthcare experts established to help guide the company’s clinical and commercial strategy. Diabetes care expert Robert Gabbay, MD, PhD, FACP was appointed as chair of the Pivot Innovation Council. The council will provide insights on target patient populations, support optimization of clinical workflows, inform evidence-generation initiatives, and help refine the Pivot product roadmap and go-to-market approach, as the Company continues to scale its differentiated offering.

Modular released findings (July 15) from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel.

Modular Medical announced (July 14) announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026. Key findings from the assessment of 100 individuals utilizing multiple daily injections revealed significant unmet needs and strong interest in simplified insulin pump technology: 1) 97% of participants stated they would be interested in insulin pump therapy and expressed openness to alternative treatment options, 2) Among the 43% of participants who reported being hospitalized due to hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS), nearly half reported experiencing such events two or more times annually, & 3) 55% of participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while 31% experienced these situations more than four times per week.

Modular Medical (June 30) announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical’s commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.

MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.

Similarweb Ltd. (NYSE: SMWB)

Similarweb Ltd. (NYSE: SMWB, $7.19 +5.27%), a leading digital data and analytics company powering critical business decisions, will release second quarter 2026 financial results for the period ended June 30, 2026, before the market opens on Wednesday, August 12, 2026.

SMWB announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

The InterGroup Corporation (INTG)

The InterGroup Corporation (NASDAQ: INTG), a diversified holding company with interests in hospitality, real estate, and marketable securities. InterGroup consolidates its majority‑owned subsidiary Portsmouth Square, Inc., which owns the Hilton San Francisco Financial District hotel and related facilities, closed at $28.91.

LG Display Co., Ltd. (LPL)

LG Display Co., Ltd. (NYSE: LPL, $2.93) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.

Yatsen Group (NYSE: YSG)

Yatsen Group (NYSE: YSG, $3.43,+1.18%), a world-class beauty innovation pioneer, announced (July 8) a landmark collaboration to bring its flagship brand, Perfect Diary, to Sephora in China. This partnership integrates Yatsen’s rigorous scientific infrastructure with the world’s leading prestige beauty retailer, marking a significant milestone in Yatsen’s continuing evolution into a global beauty technology powerhouse.

Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE: DOCS, $21.44, +2.14%) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

Doximity, Inc. will report financial results for its fiscal first quarter ended June 30, 2026 after market close on August 6, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com/.

Sable Offshore Corp. (SOC)

Sable Offshore Corp. (SOC, $4.14) is rebooting a controversial but strategically important offshore-pipeline system under federal DPA orders, targeting meaningful production from Platform Hondo while juggling financing needs that could run into the billions and regulatory battles that could reshape California’s energy landscape.

IMAX Corporation (NYSE: IMAX)

IMAX Corporation (NYSE: IMAX, $47.29, +4.83%) reported (July 23) strong financial results for the second quarter of 2026, demonstrating the value of its unique global entertainment platform and broad content portfolio.Underscoring the power of its global platform, IMAX exceeds consensus expectations and posts strong year-over-year growth for the second quarter across key metrics: Revenue of $103 million, up 12% year-over-year, Strong operating profitability with Net Income margin of 15.5% and Adjusted EBITDA(3) margin of 46.6%, Net income per diluted share of 27 cents, up 35% year-over year and record Q2 Adjusted EPS(2,3) of 43 cents, up 65% year-over-year, & Year-to-date Cash from Operating Activities of $36 million, up 19% year-over-year.

AMC Theatres (NYSE:AMC, $2.67, +6.37% ) announced that The Odyssey has delivered the highest IMAX box office revenue ever recorded at its cinemas during the first two weekends of a film’s release.

The Sources

1. CNBC – Stock Market Today Live Updates (July 27, 2026)
   https://www.cnbc.com/2026/07/27/stock-market-today-live-updates.html
2. Yahoo Finance – Stock Market Today, Tuesday July 28, 2026 (Dow, S&P 500, Nasdaq, chip stocks)
   https://finance.yahoo.com/markets/live/stock-market-today-tuesday-july-28-dow-sp-500-nasdaq-chip-stocks-082832371.html
3. CNBC – Ford Motor (F) Q2 2026 Earnings
   https://www.cnbc.com/2026/07/28/ford-motor-f-earnings-q2-2026.html
4. Yahoo Finance – Coca‑Cola (KO) Second Quarter Earnings Article
   https://finance.yahoo.com/markets/stocks/articles/coca-cola-reports-second-quarter-105500738.html
5. Ford Motor Company (F) – Investor Relations Home Page / Q2 2026 Earnings Materials
   https://shareholder.ford.com/Home/default.aspx
6. The Coca‑Cola Company (KO) – Investor Relations Press Release: “Coca‑Cola Reports Second Quarter 2026 Results…”
   https://investors.coca-colacompany.com/news-events/press-releases
7. Polymarket – Federal Reserve Rates Dashboard
   https://polymarket.com/dashboards/fed-rates
8. Polymarket – Interest Rates Predictions & Real‑Time Odds
   https://polymarket.com/predictions/interest-rates
9. Trading Economics – United States Stock Market Index Quote
   https://tradingeconomics.com/united-states/stock-market